METUBINE IODIDE Drug Patent Profile
✉ Email this page to a colleague
When do Metubine Iodide patents expire, and when can generic versions of Metubine Iodide launch?
Metubine Iodide is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in METUBINE IODIDE is metocurine iodide. There is one drug master file entry for this compound. Additional details are available on the metocurine iodide profile page.
Summary for METUBINE IODIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Patent Applications: | 673 |
Formulation / Manufacturing: | see details |
DailyMed Link: | METUBINE IODIDE at DailyMed |
US Patents and Regulatory Information for METUBINE IODIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | METUBINE IODIDE | metocurine iodide | INJECTABLE;INJECTION | 006632-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |